Amneal Pharmaceuticals, Inc.
AMRX
$7.36
$0.182.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -116.89M | -184.45M | -174.62M | -168.69M | -83.99M |
| Total Depreciation and Amortization | 236.19M | 226.99M | 225.24M | 226.78M | 229.40M |
| Total Amortization of Deferred Charges | 29.10M | 7.33M | 8.25M | 9.78M | 11.55M |
| Total Other Non-Cash Items | 150.77M | 235.20M | 243.32M | 247.03M | 235.81M |
| Change in Net Operating Assets | -4.07M | 27.78M | -49.73M | -113.44M | -47.19M |
| Cash from Operations | 295.10M | 312.84M | 252.46M | 201.46M | 345.58M |
| Capital Expenditure | -60.34M | -49.67M | -45.03M | -45.46M | -46.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 11.99M | 4.99M | 4.99M | -- | -- |
| Other Investing Activities | -14.65M | -33.95M | -31.35M | -31.75M | -22.39M |
| Cash from Investing | -63.00M | -78.63M | -71.39M | -77.21M | -69.19M |
| Total Debt Issued | 48.00M | 374.73M | 384.73M | 404.73M | 436.73M |
| Total Debt Repaid | -233.12M | -440.15M | -416.89M | -404.80M | -414.08M |
| Issuance of Common Stock | 1.15M | 1.05M | 837.00K | 479.00K | 451.00K |
| Repurchase of Common Stock | -7.95M | -7.72M | -7.72M | -7.57M | -2.38M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.88M | -179.32M | -206.62M | -215.67M | -233.30M |
| Cash from Financing | -211.79M | -251.42M | -245.66M | -222.83M | -212.57M |
| Foreign Exchange rate Adjustments | -999.00K | -58.00K | -366.00K | -867.00K | 65.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.31M | -17.26M | -64.96M | -99.45M | 63.88M |